Introduction to Tuberculosis

Mycobacterium tuberculosis and Tuberculosis Disease Introduction Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis. Understanding TB requires learning three key concepts: (1) why the bacteria persist in the body, (2) how the disease progresses from infection to active disease, and (3) how it can be diagnosed and treated. This guide walks through each of these essentials. Bacterial Characteristics and Persistence The Waxy Cell Wall Mycobacterium tuberculosis has an unusually thick, waxy cell wall that distinguishes it from most other bacteria. This waxy layer is composed of complex lipids that make the bacterium: Resistant to ordinary cleaning agents and disinfectants Difficult for the immune system to kill directly Able to survive harsh conditions, including stomach acid Why the Waxy Wall Matters The most important consequence of this waxy cell wall is that it allows the bacteria to survive inside immune cells called macrophages for prolonged periods. Normally, macrophages are designed to engulf and destroy invading pathogens, but TB bacteria resist destruction and can persist within these cells. This is a critical point: TB doesn't just hide from the immune system—it actually hides inside immune cells. This intracellular persistence is why TB is so difficult to treat and why it requires extended antibiotic therapy. Infection Process: From Inhalation to Intracellular Survival When a person with active TB coughs, sneezes, or talks, they release tiny droplets containing viable TB bacteria into the air. A nearby person who inhales these droplets allows the bacteria to reach the alveoli (air sacs) deep within the lungs, where gas exchange normally occurs. Once in the lungs, the bacteria are immediately encountered by macrophages, which engulf them—a process called phagocytosis. However, instead of being destroyed, the TB bacteria survive within these macrophages and begin to multiply slowly. This intracellular location provides protection from antibodies and other immune mechanisms that operate outside cells. Key takeaway: TB bacteria are not eliminated by the initial immune response; instead, they establish themselves inside immune cells where they can persist for years. The Two Stages of TB Infection: Latent and Active Disease Understanding the distinction between latent and active TB is crucial, as they represent different stages of the same infection with very different implications. Latent Tuberculosis Infection In a person with a healthy, functioning immune system, the body's T cells and macrophages eventually contain the infection. The bacteria become trapped inside a small, calcified lesion called a granuloma. A granuloma is essentially a walled-off collection of immune cells that surrounds the bacteria, preventing further spread. In latent TB infection: The person has no symptoms They are NOT contagious to others The infection is contained but not eliminated The bacteria remain dormant but viable (living) Latent TB can be detected through screening tests (discussed later), but the person appears and feels completely healthy. Approximately 20-30% of people with latent TB will eventually develop active disease if left untreated. Active Tuberculosis Disease Active TB develops when the immune system weakens and can no longer contain the granuloma. When this occurs, the bacteria break out and multiply rapidly throughout the lungs (or other organs), causing symptoms and tissue damage. If the immune system is weakened by: HIV infection (the most significant risk factor) Malnutrition Advanced aging Immunosuppressive medications ...the risk of progression from latent to active disease increases dramatically. Active TB can manifest in two forms: Pulmonary tuberculosis affects the lungs and is the most common form, making the person highly contagious through respiratory droplets. Extrapulmonary tuberculosis affects organs outside the lungs, such as lymph nodes, bones, kidneys, or the meninges (brain lining). While serious, extrapulmonary TB is generally not contagious. Clinical Presentation of Active Tuberculosis Pulmonary TB Symptoms The classic presentation of pulmonary TB includes: Persistent cough lasting more than 3 weeks (the hallmark symptom) Cough that may produce sputum, sometimes with blood-tinged appearance Systemic Symptoms Active TB causes general systemic symptoms due to the body's inflammatory response to the bacterial infection: Fever (often low-grade and occurring in afternoons/evenings) Night sweats (sometimes severe enough to soak clothing) Weight loss and loss of appetite Fatigue and general weakness These systemic symptoms reflect the body's ongoing battle with the infection and are common across many serious infections. Extrapulmonary TB When TB spreads to organs other than the lungs, symptoms depend on the affected organ. Common sites and presentations include: Lymph nodes: swelling and tender lymph nodes Bones: bone pain and structural damage Kidneys and urinary tract: blood in urine, urinary symptoms Meninges: meningitis symptoms including headache and stiff neck The image below shows the various symptoms associated with TB disease across different organ systems: Transmission of Tuberculosis The Airborne Route TB is transmitted almost exclusively through the airborne route. When a person with active pulmonary TB coughs, sneezes, speaks, or sings, they release infectious droplets containing TB bacteria directly into the air. These are not large, wet droplets that fall quickly; rather, they are fine droplets that can remain suspended in the air for hours, especially in indoor environments. Risk Factors for Transmission Transmission is more likely in: Crowded indoor spaces where air circulation is poor Environments with prolonged close contact (hours rather than brief exposure) Settings with inadequate ventilation A single person with untreated pulmonary TB can infect 10-15 people over a year if they remain untreated and in contact with others. However, brief, casual contact outdoors poses minimal risk. Important: People with latent TB infection are not contagious, even though the infection is present. Only those with active pulmonary TB disease spread the infection. Diagnosis of Tuberculosis Diagnosing TB requires a combination of approaches because no single test is definitive. Screening Tests Two primary screening methods are used: Tuberculin skin test (TST) or Mantoux test: A small amount of purified protein derivative (PPD) is injected into the skin. If the person has TB infection (latent or active), their immune system will react, causing local inflammation that is measured 48-72 hours later. A positive TST indicates TB infection but does NOT distinguish between latent and active disease. Blood tests (such as interferon-gamma release assays) detect TB-specific immune responses in blood and serve the same purpose as the TST. These are increasingly used as they are more specific than TST. Imaging Studies Chest X-rays are performed to detect abnormalities suggestive of pulmonary TB. Classic findings include: Infiltrates (areas of consolidation) in the upper lobes Cavitary lesions (holes in lung tissue) Granulomas A normal chest X-ray does not rule out TB, but compatible findings plus positive screening results strongly suggest active disease. Microbiological Confirmation This is the gold standard for diagnosis. Sputum samples (the material coughed up from the lungs) are collected and examined in two ways: Microscopy: Specially stained sputum is examined under a microscope for acid-fast bacilli (the TB bacteria stain differently due to their waxy wall). A person whose sputum shows bacteria is considered highly contagious and is labeled "smear-positive." Culture: Sputum is grown in special media, which takes 2-4 weeks but is more sensitive than microscopy and allows for drug susceptibility testing. Interpretation and Diagnosis Active TB is confirmed when: Screening test is positive AND Chest X-ray shows compatible findings AND TB bacteria are identified in sputum (by microscopy or culture) Latent TB is diagnosed when: Screening test is positive BUT Chest X-ray is normal AND No symptoms are present Treatment of Tuberculosis First-Line Antibiotics TB is treated with a combination of antibiotics taken over an extended period. The four first-line drugs are: Isoniazid (INH) Rifampin (or Rifampicin) Ethambutol (EMB) Pyrazinamide (PZA) Treatment Regimen The standard regimen is: Intensive phase (2 months): All four drugs together Continuation phase (4 months): Isoniazid and rifampin only Total duration: At least 6 months for drug-susceptible TB. Why Multi-Drug Therapy? Using multiple antibiotics simultaneously serves a critical purpose: prevention of drug resistance. Here's why this matters: TB bacteria multiply slowly but continuously. Within any large population of bacteria, some individuals randomly develop mutations that confer resistance to a particular antibiotic. If only one drug is used, these resistant bacteria will survive while susceptible bacteria are killed, eventually leaving a population of resistant organisms. However, the probability of a single bacterium being resistant to all four drugs simultaneously is extremely low. By using four drugs together, susceptible bacteria are killed by each drug, and any bacteria resistant to one drug are likely killed by the other three. This combination approach is what prevents the emergence of multidrug-resistant tuberculosis (MDR-TB), which is much harder and longer to treat. Adherence is Critical Because TB bacteria persist intracellularly and multiply slowly, the full 6-month course is necessary to eradicate all bacteria. Stopping early—even if symptoms resolve—leaves viable bacteria that can: Cause relapse (the disease returns) Develop drug resistance Patients who do not complete the full course are at high risk for developing resistant TB, which is a major public health problem. Prevention and Public Health Strategies BCG Vaccination The Bacillus Calmette-Guérin (BCG) vaccine is a live attenuated (weakened) vaccine that is administered to infants in many countries, particularly in regions with high TB burden. BCG vaccination: Provides strong protection against severe TB forms in children (like TB meningitis) Protection wanes over time Is less effective at preventing pulmonary TB in adults The vaccine is not used as widely in countries with low TB burden and good healthcare systems, as the risk is lower and the vaccine can complicate TST interpretation. Case Detection and Isolation Public health control of TB depends on: Early identification of people with active TB through screening and clinical awareness Isolation of contagious patients (those with active pulmonary TB) from the general population until they have received 2 weeks of appropriate therapy Once treatment is underway, TB bacteria rapidly decrease, and patients become non-contagious Treatment Adherence Programs Ensuring patients complete their full 6-month course is essential. Strategies include: Directly observed therapy (DOT): A healthcare worker observes the patient actually swallowing each dose of medication. This dramatically improves completion rates and prevents drug resistance. Patient education: Explaining why the full course is necessary even after symptoms resolve. Removal of barriers: Providing free medications, addressing transportation or work issues, and managing side effects. Special Considerations: HIV and TB Co-infection The HIV-TB Connection Co-infection with human immunodeficiency virus (HIV) profoundly changes TB epidemiology and outcomes: Dramatically increased risk: People with HIV are 20-30 times more likely to develop active TB compared to HIV-negative individuals More severe disease: HIV weakens the immune system's ability to contain TB, leading to: More rapid progression from latent to active disease Higher rates of extrapulmonary TB More severe symptoms Higher mortality rates Diagnostic challenges: People with advanced HIV and very low CD4 counts may have atypical TB presentations that are difficult to diagnose In regions with both high HIV and TB prevalence, HIV-TB co-infection is a major public health crisis. TB is one of the leading causes of death in people living with HIV who are not on appropriate antiretroviral therapy. <extrainfo> Global TB Burden Tuberculosis remains the leading cause of death from a single infectious agent globally. The disease disproportionately affects low- and middle-income countries, where: Limited diagnostic facilities delay detection Treatment access and adherence support are inadequate Malnutrition and co-infections like HIV are more common Crowded living conditions facilitate transmission In high-income countries with good healthcare infrastructure, TB incidence has declined dramatically, but it remains important as an infection that can progress and spread if not detected and treated. </extrainfo> Summary of Key Concepts | Concept | Key Point | |---------|-----------| | Persistence | TB's waxy cell wall allows survival inside macrophages | | Latent vs. Active | Latent: contained, asymptomatic, non-contagious; Active: symptomatic, contagious, progressive | | Transmission | Airborne route in crowded, poorly ventilated indoor spaces | | Symptoms | Pulmonary: persistent cough; Systemic: fever, night sweats, weight loss, fatigue | | Diagnosis | Combination of screening test, chest X-ray, and sputum examination | | Treatment | 4-drug combination for 2 months, then 2-drug therapy for 4 months (6 months total) | | Drug Resistance | Prevented by multi-drug therapy and treatment adherence | | Prevention | BCG vaccination, case detection, isolation, treatment adherence programs |